S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
NASDAQ:CRBP

Corbus Pharmaceuticals - CRBP Stock Forecast, Price & News

$0.22
+0.01 (+4.73%)
(As of 08/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.21
$0.24
50-Day Range
$0.21
$0.30
52-Week Range
$0.21
$1.32
Volume
3.79 million shs
Average Volume
1.24 million shs
Market Capitalization
$27.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.50

Corbus Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
1,028.7% Upside
$2.50 Price Target
Short Interest
Healthy
2.61% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.65
Upright™ Environmental Score
News Sentiment
0.89mentions of Corbus Pharmaceuticals in the last 14 days
Based on 7 Articles This Week
Insider Trading
Acquiring Shares
$7,438 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.19) to ($0.30) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.49 out of 5 stars

Medical Sector

207th out of 1,119 stocks

Pharmaceutical Preparations Industry

89th out of 549 stocks

CRBP stock logo

About Corbus Pharmaceuticals (NASDAQ:CRBP) Stock

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on Corbus Pharmaceuticals in a research report on Friday, August 12th. They set a "hold" rating for the company.

Corbus Pharmaceuticals Price Performance

Shares of CRBP Stock opened at $0.21 on Thursday. Corbus Pharmaceuticals has a 12 month low of $0.21 and a 12 month high of $1.32. The stock has a 50 day moving average of $0.27 and a 200-day moving average of $0.34. The company has a current ratio of 4.81, a quick ratio of 4.81 and a debt-to-equity ratio of 0.23.

Receive CRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRBP Stock News Headlines

Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Corbus Pharmaceuticals: Q4 Earnings Insights
CRBP Jan 2023 2.500 call
See More Headlines
Receive CRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRBP Company Calendar

Last Earnings
11/12/2021
Today
8/18/2022
Next Earnings (Estimated)
11/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRBP
Employees
41
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.50
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+1,028.7%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-45,640,000.00
Pretax Margin
-36,209.27%

Debt

Sales & Book Value

Annual Sales
$880,000.00
Book Value
$0.39 per share

Miscellaneous

Free Float
114,996,000
Market Cap
$27.75 million
Optionable
Optionable
Beta
1.94

Key Executives

  • Dr. Yuval Cohen Ph.D. (Age 47)
    CEO & Director
    Comp: $846.92k
  • Mr. Sean F. Moran CPA (Age 64)
    M.B.A., CPA, MBA, Chief Financial Officer
    Comp: $542k
  • Mr. Craig Stuart Millian M.B.A. (Age 53)
    Chief Operating Officer
    Comp: $542k
  • Dr. Rachael Brake Ph.D. (Age 50)
    Chief Scientific Officer
  • Ted Jenkins
    Sr. Director of Investor Relations & Corp. Communications
  • Ms. Lindsey Smith
    Head of Corp. Communications & Patient Advocacy
  • Ms. Christina Bertsch
    Head of HR
  • Scott Constantine
    Sr. Director & Head of Clinical Operations













CRBP Stock - Frequently Asked Questions

Should I buy or sell Corbus Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CRBP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRBP, but not buy additional shares or sell existing shares.
View CRBP analyst ratings
or view top-rated stocks.

What is Corbus Pharmaceuticals' stock price forecast for 2022?

3 analysts have issued 1-year target prices for Corbus Pharmaceuticals' stock. Their CRBP share price forecasts range from $2.00 to $3.00. On average, they anticipate the company's share price to reach $2.50 in the next twelve months. This suggests a possible upside of 1,065.5% from the stock's current price.
View analysts price targets for CRBP
or view top-rated stocks among Wall Street analysts.

How have CRBP shares performed in 2022?

Corbus Pharmaceuticals' stock was trading at $0.6157 on January 1st, 2022. Since then, CRBP shares have decreased by 65.2% and is now trading at $0.2145.
View the best growth stocks for 2022 here
.

When is Corbus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our CRBP earnings forecast
.

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) released its quarterly earnings data on Friday, November, 12th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.10. The biopharmaceutical company earned $0.10 million during the quarter, compared to the consensus estimate of $0.81 million.

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and KushCo (KSHB).

What is Corbus Pharmaceuticals' stock symbol?

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

Who are Corbus Pharmaceuticals' major shareholders?

Corbus Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Mirae Asset Global Investments Co. Ltd. (3.22%), Renaissance Technologies LLC (1.30%), Ikarian Capital LLC (0.69%), Millennium Management LLC (0.28%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Barbara White, Craig Stuart Millian, Robert Paul Discordia, Sean F Moran and Yuval Cohen.
View institutional ownership trends
.

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corbus Pharmaceuticals' stock price today?

One share of CRBP stock can currently be purchased for approximately $0.21.

How much money does Corbus Pharmaceuticals make?

Corbus Pharmaceuticals (NASDAQ:CRBP) has a market capitalization of $26.87 million and generates $880,000.00 in revenue each year. The biopharmaceutical company earns $-45,640,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis.

How can I contact Corbus Pharmaceuticals?

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The official website for the company is www.corbuspharma.com. The biopharmaceutical company can be reached via phone at (617) 963-0100, via email at ir@corbuspharma.com, or via fax at 617-663-6085.

This page (NASDAQ:CRBP) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.